Bill > S786

This bill directs the Health Policy Commission to conduct a study examining the feasibility of establishing a state-run program to manufacture generic or biosimilar prescription drugs. The study aims to analyze whether such a program would increase competition, lower drug prices, and address shortages in the prescription drug market, as well as reduce healthcare costs for the state. The study will also identify the factors contributing to high drug prices, particularly for older, off-patent, or generic drugs, and assess the potential impact of a state-run drug manufacturing program on prescription drug and healthcare costs in Massachusetts. The Commission is required to submit a report with its findings and recommendations within one year, including a cost-benefit analysis and a plan for establishing such a program if deemed effective.

Health and Social Services

https://malegislature.gov/Bills/192/S786